|Awarded On||September 14, 2022|
|Title||Ultrasensitive Nanosensor-Based Detection of Tumor Immunogenic Peptides to Enable Personalized Cancer Immunotherapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Arlington|
|Principal Investigator/Program Director||Georgios Alexandrakis|
|Cancer Sites||Colorectal, Lung and Bronchus|
*Pending contract negotiation
Precision medicine technologies enabling a physician to prescribe the most effective personalized treatment available to each patient with cancer are evolving rapidly and could spare patients from ineffective treatments and their side effects. This work proposes to build and test a unique sensor that can help address this important need and provide actionable information to the doctor. The proposed novel nanosensor technology aims to enable monitoring if and how effectively the body's T-cells can recognize small pieces of cancer-derived specific proteins that are presented by specialized surface complexes on cancer cells in a patient's tumor. Recognition of these small protein pieces can tri...